GT
IGMS

Glenmede Trust’s IGM Biosciences IGMS Stock Holding History

Glenmede Trust’s Portfolio IGMS Stock Details IGMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-4,355
Closed -$362K – 1311
2021
Q2 		$362K Sell
4,355
-187
-4% -$13.9K ﹤0.01% 979
2021
Q1 		$348K Buy
4,542
+1,712
+60% +$156K ﹤0.01% 942
2020
Q4 		$249K Sell
2,830
-1,705
-38% -$120K ﹤0.01% 1007
2020
Q3 		$334K Buy
4,535
+2,780
+158% +$165K ﹤0.01% 894
2020
Q2 		$128K Buy
+1,755
New +$107K ﹤0.01% 1105

Other funds holding IGMS

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Glenmede Trust's IGMS Position: Q3 2021 in Review

Glenmede Trust sold out of IGM Biosciences (IGMS) in Q3 2021, closing a stake of 4,355 shares — an estimated $362K sold.

Glenmede Trust first reported a position in IGMS in Q2 2020 and held it in 5 quarters. The position peaked at $362K in Q2 2021. 107 funds tracked by Wall St. Rank hold IGMS as of Q3 2021.

  • Glenmede Trust reported no remaining IGM Biosciences position as of Q3 2021 after selling out during the quarter.
  • Glenmede Trust sold 4,355 IGM Biosciences shares in Q3 2021, an estimated $362K.
  • Glenmede Trust first reported a position in IGM Biosciences in Q2 2020 and held it in 5 quarters.
  • Glenmede Trust's IGM Biosciences position peaked at $362K in Q2 2021.
  • 107 funds tracked by Wall St. Rank held IGM Biosciences as of Q3 2021.

Based on Glenmede Trust's 13F filing for Q3 2021, filed 15 Nov 2021.